AIMOVIG Drug Profile

Summary for Tradename: AIMOVIG

High Confidence Patents:	5
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for AIMOVIG
Recent Clinical Trials:	See clinical trials for AIMOVIG

See drug prices for AIMOVIG

Recent Clinical Trials for AIMOVIG

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 2
Recordati Rare Diseases	Phase 2
AbbVie	Phase 4

See all AIMOVIG clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for AIMOVIG Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for AIMOVIG Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	10,259,877	2036-04-22	DrugPatentWatch analysis and company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	11,407,838	2039-04-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	11,466,090	2039-02-27	DrugPatentWatch analysis and company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	9,102,731	2029-12-18	DrugPatentWatch analysis and company disclosures
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	9,862,771	2035-06-26	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for AIMOVIG Derived from Patent Text Search

No patents found based on company disclosures

International Patents for AIMOVIG

Country	Patent Number	Estimated Expiration
Jordan	3382
Philippines	12017501934
Lithuania	3653225
Singapore	10202004282R
Taiwan	I728953
World Intellectual Property Organization (WIPO)	2019195185

Supplementary Protection Certificates for AIMOVIG

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2018 00042	Denmark		PRODUCT NAME: ERENUMAB; REG. NO/DATE: EU/1/18/1293 20180730
338 22-2018	Slovakia		PRODUCT NAME: ERENUMAB; REGISTRATION NO/DATE: EU/1/18/1293 20180730
50/2018	Austria		PRODUCT NAME: ERENUMAB; REGISTRATION NO/DATE: EU/1/18/1293 (MITTEILUNG) 20180730
2018042	Norway		PRODUCT NAME: ERENUMAB; REG. NO/DATE: 20180730
CA 2018 00042	Denmark		PRODUCT NAME: ERENUMAB; REG. NO/DATE: EU/1/18/1293 20180730
669	Finland

Market Dynamics and Financial Trajectory for AIMOVIG

Last updated: February 19, 2026

What is AIMOVIG and What is Its Market Position?

AIMOVIG (erenumab) is a monoclonal antibody developed by Novartis that targets the calcitonin gene-related peptide (CGRP) receptor to prevent migraines. Launched in 2018, it holds a significant position as one of the first CGRP inhibitors approved for migraine prevention.

How Has the Market for Migraine Prevention Evolved?

The migraine treatment market includes both traditional prophylactics and newer biologics like AIMOVIG. Prior to CGRP inhibitors, options included beta-blockers, antiepileptics, and antidepressants. Despite these, a substantial unmet need persisted, particularly for patients with frequent migraines and intolerant to oral therapies.

The global migraine medication market was valued at USD 3.52 billion in 2022. It projects a CAGR of 6.9% from 2023 to 2030, reaching USD 5.65 billion. The growth is driven by increased awareness and the approval of targeted biologics.

How has AIMOVIG's sales evolved?

According to Novartis’ earnings reports, AIMOVIG generated USD 967 million in net sales in 2022, representing a 21% increase from 2021. In 2020, the drug posted USD 626 million. Sales registered a compound annual growth rate of approximately 32.7% from 2020 to 2022.

Year	Net Sales (USD Millions)	Growth Rate
2020	626	-
2021	800	27.7%
2022	967	21%

Major markets include the U.S., European Union, and Japan. The U.S. accounted for roughly 70% of total sales in 2022.

What Factors Influence AIMOVIG’s Market Share?

• Competitive landscape: Presence of other CGRP antagonists like Eli Lilly's Emgality (galcanezumab) and Teva's Ajovy (fremanezumab). In 2022, Emgality generated USD 340 million globally, tightening competition.
• Pricing and reimbursement: Negotiations with payers impact accessibility. U.S. list price was approximately USD 575 per dose, with net prices declining due to discounts.
• Patient preferences: Once-monthly subcutaneous injections are preferred over oral or less frequent therapies.
• Regulatory approvals: Expansion into preventive treatments for other migraine types expands addressable market.

How Do Patent and Regulatory Developments Impact Financial Trajectory?

Novartis holds orphan drug exclusivity for erenumab in the U.S. until 2028. Patent expirations in other regions may open the market to biosimilars or generics, potentially reducing prices. However, no biosimilar entrants are currently authorized for erenumab globally.

Regulatory bodies like the FDA and EMA continue to approve expanded indications, including episodic and chronic migraine, cementing AIMOVIG’s market position and growth prospects.

What Are the Key Risks and Opportunities?

Risks:

• Patent expirations in key markets may lead to generic competition.
• Patient access and reimbursement policies could restrict sales.
• Development of alternative migraine therapies, including oral options, might dilute market share.

Opportunities:

• Expansion into episodic and chronic cluster headaches.
• New formulations, such as combination therapies or improved delivery mechanisms.
• Market penetration in emerging regions like China and Latin America.

What Is the Future Revenue Outlook?

Forecasts estimate AIMOVIG’s global sales will reach USD 1.1–1.3 billion annually by 2025, assuming continued market expansion and stable pricing strategies. The CAGR for AIMOVIG is projected around 12%-15% over the next three years, aligned with migraine prevalence growth and increased adoption rates.

Summary of Financial Data

Metric	2020	2021	2022	CAGR (2020–2022)
Net Sales	USD 626 million	USD 800 million	USD 967 million	32.7%

Key Takeaways

• AIMOVIG maintains a strong growth trajectory driven by unmet needs and expanding indications.
• Competitive pressures and patent cliffs are primary risks to sustained revenue.
• The market for biologics in migraine prevention is expanding at a CAGR of approximately 6.9%, with AIMOVIG capturing a significant share.
• Future growth will depend on market expansion, regulatory approvals, and pricing strategies.

5 FAQs

1. What is the primary mechanism of AIMOVIG?
It blocks the CGRP receptor to prevent migraine attacks.

2. What are the main competitors?
Eli Lilly's Emgality (galcanezumab) and Teva's Ajovy (fremanezumab).

3. When does patent protection expire?
In the U.S., orphan drug exclusivity lasts until 2028; other regions vary.

4. How does pricing impact sales?
High list prices are offset by discounts and reimbursement negotiations, affecting net revenue.

5. What markets show the most growth potential?
Emerging markets like China and Latin America, where migraine prevalence is rising and biologics are less penetrated.

---

References

[1] Novartis. (2023). Annual report 2022.
[2] Markets and Markets. (2022). Migraine drugs market trend report.
[3] U.S. Food & Drug Administration. (2018). Approval documents for AIMOVIG.
[4] IQVIA. (2023). Global migraine medications overview.
[5] European Medicines Agency. (2022). Erenumab marketing authorization summary.